Zydus Lifesciences Reports 17% Revenue Growth to Rs 271.5 Billion

Revenue hit Rs 271.5 billion in FY2026, marking a 17% jump, while the company eyes being debt-free by FY2028.

Reader Takeaway: Strong operational margins and capital return plans, offset by ongoing regulatory scrutiny in the US market.

What just happened

Zydus Lifesciences showcased a robust financial performance for FY2025-26, supported by strong margins and clear capital allocation strategies. The company reported a 31.2% EBITDA margin and committed to distributing approximately 30% of profits back to shareholders through a combination of dividends and the newly approved Rs 1,100 crore share buyback at Rs 1,260 per share.

Why this matters

The company’s pivot toward becoming debt-free in two years is a major highlight for investors looking for balance sheet stability. Furthermore, the commitment to reinvesting nearly 8% of revenue into R&D underlines a shift toward high-value innovation, specifically in the biosimilars segment and its flagship NCE, Saroglitazar, which is nearing its US market launch.

Strategic Growth Areas

Zydus is leveraging recent acquisitions like Comfort Click and Amplitude Surgical to sharpen its focus on digital-first consumer channels and specialized orthopaedic implants. Management expressed confidence in its ability to navigate the US pricing landscape, noting that their supply chains are resilient enough to handle current regulatory and tariff pressures.

Management Outlook

Leadership addressed shareholder concerns regarding plant inspections, confirming that their facilities remain in strong standing with global regulators. While the US market remains a core revenue driver, the company is also doubling down on its domestic market leadership for semaglutide products.

What to track next

Investors should closely monitor the US FDA regulatory process for the Saroglitazar NDA. The planned US launch in Q4 FY2027 is a crucial catalyst for the company’s stated ambition of maintaining high-teen revenue growth.